Lord Mendelsohn

To ask His Majesty's Government, further to the Written Answer by the Minister of State for the Department of Health and Social Care on 27 January (127906), what the scope of the Covid antibody study will be; which body will be tasked to deliver the study...

To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 21 June 2022 (HL728), what is the "recent evidence" that "antivirals and neutralising monoclonal antibodies significantly improve clinical outcomes in non-hospitalised patien...

To ask His Majesty's Government when the COVID-19 Therapeutics Clinical Review Panel held its last meeting; and whether the strategy to support at-risk patient cohorts has been recently reviewed, with particular reference to the accessibility of (1) Evush...

To ask His Majesty's Government what data the COVID-19 Therapeutics Clinical Review Panel are currently reviewing to inform its advice to Government in relation to support for at-risk patient cohorts.

To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 23 June 2022 (HL731), whether they will publish the observational data on treatment outcomes referred to in the Answer.

To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 12 April 2022 (HL7711), given the data referred to, what update they can provide on (1) evidence of immune response in immunocompromised and immunosuppressed patients, and (2...

To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), what work was undertaken by NHS Digital in June 2022 (1) to improve the access to relevant data which identifies those who are immunocompromised, and (2)...

To ask His Majesty's Government what assessment they have made of the equalities impact of replacing the COVID-19 Medicines Delivery Units in order to move COVID-19 therapeutics delivery to primary care.

To ask His Majesty's Government, further to the publication of the RAPID C-19 Oversight Group report on 6 October, whether the Antivirals and Therapeutics Taskforce has determined the nature and threshold of evidence required for a prophylactic monoclonal...

To ask His Majesty's Government what percentage of people who received COVID-19 treatment in a community setting subsequently died from COVID-19.

To ask His Majesty's Government whether they will ensure that immunocompromised patients will have to wait no more than nine months from approval to get the prophylactic antibodies Evusheld.

To ask His Majesty's Government what papers and data were consulted in advance of the Secretary of State for Health and Social Care and Chief Medical Officer taking the decision not to pursue procurement of Evusheld; and what is the most recent real time ...

To ask His Majesty's Government, further to the report by OpenSAFELY on behalf of NHS England, published on 13 October, which showed that 25 per cent of potentially eligible White patients received treatments through the Covid Medicines Delivery Unit (CMD...

To ask His Majesty's Government what plans they have to undertake an equalities assessment on the availability of protection from COVID-19, given that immunocompromised and vulnerable patients' only access to Evusheld costs up to £3,000 on the private mar...

To ask His Majesty's Government what assessment they have made of the position that coronavirus vaccines and immunizations, including prophylactic antibodies, should be assessed through the JCVI.

To ask His Majesty's Government what assessment they have made, if any, of (1) a report by BioMed Central (BMD) which suggests that the average length of stay in hospital for COVID-19 patients in England is between 16-29 days; and (2) a report by the US N...

To ask His Majesty's Government whether a recommendation by Rapid C-19 is stopping the provision of Evusheld in the NHS by Christmas.

To ask His Majesty's Government whether Evusheld will be available to NHS patients before Christmas.

To ask His Majesty's Government whether they will rule out the possibility that patients will receive a placebo in place of Evusheld.

To ask His Majesty's Government what discussions they have had with experts in any of the 32 countries using Evusheld on their real time testing and trials.